A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive Interventions:   Biological: Granulocyte-Macrophage Colony-Stimulating Factor;   Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC;   Procedure: Therapeutic Conventional Surgery Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials